Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

Yang Yang Ding, Jessica Panzer, John M. Maris, Alicia Castañeda, Marta Gomez-Chiari, Jaume Mora

Research output: Contribution to journalArticlepeer-review


Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature. We describe three patients with clinical symptoms of transverse myelitis, confirmed via magnetic resonance imaging, shortly following initiation of dinutuximab. All patients were discontinued from dinutuximab treatment and received urgent treatment, with rapid improvement in symptoms and resultant functional recovery.

Original languageEnglish (US)
Article numbere26732
JournalPediatric Blood and Cancer
Issue number1
StatePublished - Jan 2018
Externally publishedYes


  • anti-GD2 monoclonal antibody
  • dinutuximab
  • neuroblastoma
  • transverse myelitis
  • Unituxin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this